Annals of Diagnostic Pathology
Volume 10, Issue 2 , Pages 67-71 , April 2006

Thyroid transcription factor–1 staining is useful in identifying brain metastases of pulmonary origin

References 

  1. Sawaya R, Ligon BL, Bindal RK. Management of metastatic brain tumors. Ann Surg Oncol. 1994;1:169–178
  2. Wen PY, Loeffler JS. Management of brain metastases. Oncology. 1999;13:941–957
  3. Posner JB. Management of brain metastases. Rev Neurol. 1992;148:477–487
  4. Dhopesh VP, Yagnik PM. Brain metastasis: analysis of patients without known cancer. South Med J. 1985;78:171–172
  5. Merchut MP. Brain metastases from undiagnosed systemic neoplasms. Arch Intern Med. 1989;149:1076–1080
  6. Le Chevalier T, Smith FP, Caille P, et al. Sites of primary malignancies in patients presenting with cerebral metastases. A review of 120 cases. Cancer. 1985;56:880–882
  7. Debevec M. Management of patients with brain metastases of unknown origin. Neoplasma. 1990;37:601–606
  8. Lau SK, Luthringer DJ, Eisen RN. Thyroid transcription factor–1: a review. Appl Immunohistochem Mol Morphol. 2002;10:97–102
  9. Civitareale D, Lonigro R, Sinclair AJ, et al. A thyroid-specific nuclear protein essential for tissue-specific expression of the thyroglobulin promoter. EMBO J. 1989;8:2537–2542
  10. Lazzaro D, Price M, De Felice M, et al. The transcription factor TTF-1 is expressed at the onset of thyroid and lung morphogenesis and in restricted regions of the fetal brain. Development. 1991;113:1093–1104
  11. Ordonez NG. Value of thyroid transcription factor–1 immunostaining in distinguishing small cell lung carcinomas from other small cell carcinomas. Am J Surg Pathol. 2000;24:1217–1223
  12. Ordonez NG. Thyroid transcription factor–1 is a marker of lung and thyroid carcinomas. Adv Anat Pathol. 2000;7:123–127
  13. Kaufmann O, Dietel M. Expression of thyroid transcription factor–1 in pulmonary and extrapulmonary small cell carcinomas and other neuroendocrine carcinomas of various primary sites. Histopathology. 2000;36:415–420
  14. Pelosi G, Fraggetta F, Pasini F, et al. Immunoreactivity for thyroid transcription factor–1 in stage I non–small cell carcinomas of the lung. Am J Surg Pathol. 2001;25:363–372
  15. Di Loreto C, Di Lauro V, Puglisi F, et al. Immunocytochemical expression of tissue specific transcription factor–1 in lung carcinoma. J Clin Pathol. 1997;50:30–32
  16. Reis-Filho JS, Carrilho C, Valenti C, et al. Is TTF1 a good immunohistochemical marker to distinguish primary from metastatic lung adenocarcinomas?. Pathol Res Pract. 2000;196:835–840
  17. Bohinski RJ, Bejarano PA, Balko G, et al. Determination of lung as the primary site of cerebral metastatic adenocarcinomas using monoclonal antibody to thyroid transcription factor–1. J Neurooncol. 1998;40:227–231
  18. Srodon M, Westra WH. Immunohistochemical staining for thyroid transcription factor–1: a helpful aid in discerning primary site of tumor origin in patients with brain metastases. Hum Pathol. 2002;33:642–645
  19. Ordonez NG. Value of thyroid transcription factor–1, E-cadherin, BG8, WT1, and CD44S immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary and nonpulmonary adenocarcinoma. Am J Surg Pathol. 2000;24:598–606
  20. Kaufmann O, Dietel M. Thyroid transcription factor–1 is the superior immunohistochemical marker for pulmonary adenocarcinomas and large cell carcinomas compared to surfactant proteins A and B. Histopathology. 2000;36:8–16
  21. Perry A, Parisi JE, Kurtin PJ. Metastatic adenocarcinoma to the brain: an immunohistochemical approach. Hum Pathol. 1997;28:938–943
  22. Harlamert HA, Mira J, Bejarano PA, et al. Thyroid transcription factor–1 and cytokeratins 7 and 20 in pulmonary and breast carcinoma. Acta Cytol. 1998;42:1382–1388
  23. Drlicek M, Bodenteich A, Urbanits S, Grisold W. Immunohistochemical panel of antibodies in the diagnosis of brain metastases of the unknown primary. Pathol Res Pract. 2004;200:727–734
  24. Pan C-C, Chen PC-H, Tsay S-H, Chiang H. Cytoplasmic immunoreactivity for thyroid transcription factor–1 in hepatocellular carcinomas. A comparative immunohistochemical analysis of four commercial antibodies using a tissue array technique. Am J Clin Pathol. 2004;121:343–349
  25. Wieczorek TJ, Pinkus JL, Glickman JN, Pinkus GS. Comparison of thyroid transcription factor–1 and hepatocyte antigen immunohistochemical analysis in the differential diagnosis of hepatocellular carcinoma, metastatic adenocarcinoma, renal cell carcinoma, and adrenal cortical carcinoma. Am J Clin Pathol. 2002;118:911–921
  26. Nakamura K, Kimura S, Yamazaki M, et al. Immunohistochemical analyses of thyroid-specific enhancer-binding protein in the fetal and adult rat hypothalami and pituitary glands. Brain Res Dev Brain Res. 2001;130:159–166
  27. Zamecnik J, Chanova M, Kodet R. Expression of thyroid transcription factor–1 in primary brain tumors. J Clin Pathol. 2004;57:1111–1113

PII: S1092-9134(05)00119-X

doi: 10.1016/j.anndiagpath.2005.07.013

Annals of Diagnostic Pathology
Volume 10, Issue 2 , Pages 67-71 , April 2006

Article Tools

* Image Usage & Resolution